Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

NCT05199285 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT05199285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05199285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 2
Overall status
Terminated
Start date
January 19, 2023
Completion date
February 1, 2026
Enrollment
15 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

bclc stage b hepatocellular carcinoma, bclc stage c hepatocellular carcinoma, locally advanced hepatocellular carcinoma, metastatic hepatocellular carcinoma, stage iii hepatocellular carcinoma ajcc v8, stage iiia hepatocellular carcinoma ajcc v8, stage iiib hepatocellular carcinoma ajcc v8, stage iv hepatocellular carcinoma ajcc v8, stage iva hepatocellular carcinoma ajcc v8, stage ivb hepatocellular carcinoma ajcc v8, unresectable hepatocellular carcinoma